Literature DB >> 21752960

Cyclosporin A inhibits the replication of diverse coronaviruses.

Adriaan H de Wilde1, Jessika C Zevenhoven-Dobbe1, Yvonne van der Meer1, Volker Thiel2,3, Krishna Narayanan4, Shinji Makino4, Eric J Snijder1, Martijn J van Hemert1.   

Abstract

Low micromolar, non-cytotoxic concentrations of cyclosporin A (CsA) strongly affected the replication of severe acute respiratory syndrome coronavirus (SARS-CoV), human coronavirus 229E and mouse hepatitis virus in cell culture, as was evident from the strong inhibition of GFP reporter gene expression and a reduction of up to 4 logs in progeny titres. Upon high-multiplicity infection, CsA treatment rendered SARS-CoV RNA and protein synthesis almost undetectable, suggesting an early block in replication. siRNA-mediated knockdown of the expression of the prominent CsA targets cyclophilin A and B did not affect SARS-CoV replication, suggesting either that these specific cyclophilin family members are dispensable or that the reduced expression levels suffice to support replication.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21752960      PMCID: PMC3352363          DOI: 10.1099/vir.0.034983-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  42 in total

1.  Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A.

Authors:  Sandra Ciesek; Eike Steinmann; Heiner Wedemeyer; Michael P Manns; Johann Neyts; Norbert Tautz; Vanesa Madan; Ralf Bartenschlager; Thomas von Hahn; Thomas Pietschmann
Journal:  Hepatology       Date:  2009-11       Impact factor: 17.425

2.  Quantitative proteomics analysis reveals BAG3 as a potential target to suppress severe acute respiratory syndrome coronavirus replication.

Authors:  Liang Zhang; Zhi-Ping Zhang; Xian-En Zhang; Fu-Sen Lin; Feng Ge
Journal:  J Virol       Date:  2010-04-14       Impact factor: 5.103

3.  Comparison of the effect of FK506 and cyclosporin A on virus production in H9 cells chronically and newly infected by HIV-1.

Authors:  C J Briggs; D E Ott; L V Coren; S Oroszlan; J Tözsér
Journal:  Arch Virol       Date:  1999       Impact factor: 2.574

4.  Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein.

Authors:  Min Qing; Feng Yang; Bo Zhang; Gang Zou; John M Robida; Zhiming Yuan; Hengli Tang; Pei-Yong Shi
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

5.  Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes.

Authors:  Koichi Watashi; Makoto Hijikata; Masahiro Hosaka; Masashi Yamaji; Kunitada Shimotohno
Journal:  Hepatology       Date:  2003-11       Impact factor: 17.425

6.  Requirement for cyclophilin A for the replication of vesicular stomatitis virus New Jersey serotype.

Authors:  Santanu Bose; Manjula Mathur; Patricia Bates; Nikita Joshi; Amiya K Banerjee
Journal:  J Gen Virol       Date:  2003-07       Impact factor: 3.891

7.  A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells.

Authors:  Nicolas Manel; Brandon Hogstad; Yaming Wang; David E Levy; Derya Unutmaz; Dan R Littman
Journal:  Nature       Date:  2010-09-09       Impact factor: 49.962

8.  Structural and biochemical characterization of the human cyclophilin family of peptidyl-prolyl isomerases.

Authors:  Tara L Davis; John R Walker; Valérie Campagna-Slater; Patrick J Finerty; Ragika Paramanathan; Galina Bernstein; Farrell MacKenzie; Wolfram Tempel; Hui Ouyang; Wen Hwa Lee; Elan Z Eisenmesser; Sirano Dhe-Paganon
Journal:  PLoS Biol       Date:  2010-07-27       Impact factor: 8.029

Review 9.  Hosting the severe acute respiratory syndrome coronavirus: specific cell factors required for infection.

Authors:  Cornelis A M de Haan; Peter J M Rottier
Journal:  Cell Microbiol       Date:  2006-06-27       Impact factor: 3.715

10.  Nucleocapsid protein of SARS coronavirus tightly binds to human cyclophilin A.

Authors:  Cheng Luo; Haibin Luo; Suxin Zheng; Chunshan Gui; Liduo Yue; Changying Yu; Tao Sun; Peilan He; Jing Chen; Jianhua Shen; Xiaomin Luo; Yixue Li; Hong Liu; Donglu Bai; Jingkang Shen; Yiming Yang; Fangqiu Li; Jianping Zuo; Rolf Hilgenfeld; Gang Pei; Kaixian Chen; Xu Shen; Hualiang Jiang
Journal:  Biochem Biophys Res Commun       Date:  2004-08-27       Impact factor: 3.575

View more
  112 in total

Review 1.  Drug repurposing for the treatment of COVID-19: Pharmacological aspects and synthetic approaches.

Authors:  Pedro N Batalha; Luana S M Forezi; Carolina G S Lima; Fernanda P Pauli; Fernanda C S Boechat; Maria Cecília B V de Souza; Anna C Cunha; Vitor F Ferreira; Fernando de C da Silva
Journal:  Bioorg Chem       Date:  2020-11-19       Impact factor: 5.275

2.  Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture.

Authors:  Adriaan H de Wilde; Dirk Jochmans; Clara C Posthuma; Jessika C Zevenhoven-Dobbe; Stefan van Nieuwkoop; Theo M Bestebroer; Bernadette G van den Hoogen; Johan Neyts; Eric J Snijder
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

3.  COVID-19 and Calcineurin Inhibitors: Should They Get Left Out in the Storm?

Authors:  Michelle Willicombe; David Thomas; Stephen McAdoo
Journal:  J Am Soc Nephrol       Date:  2020-04-20       Impact factor: 10.121

Review 4.  A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review.

Authors:  Priyanka Dash; Subhashree Mohapatra; Sayantan Ghosh; Bismita Nayak
Journal:  Front Pharmacol       Date:  2021-02-26       Impact factor: 5.810

5.  Adaptive Mutations in Replicase Transmembrane Subunits Can Counteract Inhibition of Equine Arteritis Virus RNA Synthesis by Cyclophilin Inhibitors.

Authors:  Eric J Snijder; Clara C Posthuma; Adriaan H de Wilde; A Linda Boomaars-van der Zanden; Anja W M de Jong; Montserrat Bárcena
Journal:  J Virol       Date:  2019-08-28       Impact factor: 5.103

6.  A Comparison Study of Coronavirus Disease 2019 Outcomes in Hospitalized Kidney Transplant Recipients.

Authors:  Sherry G Mansour; Divyanshu Malhotra; Michael Simonov; Yu Yamamoto; Tanima Arora; Labeebah Subair; Jameel Alausa; Dennis G Moledina; Jason H Greenberg; Francis Perry Wilson; Ethan P Marin
Journal:  Kidney360       Date:  2021-01-12

7.  Cyclophilin inhibitors block arterivirus replication by interfering with viral RNA synthesis.

Authors:  Adriaan H de Wilde; Yanhua Li; Yvonne van der Meer; Grégoire Vuagniaux; Robert Lysek; Ying Fang; Eric J Snijder; Martijn J van Hemert
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

Review 8.  New targets for treatment against HCV infection.

Authors:  Qiuwei Pan; Luc J W van der Laan
Journal:  Best Pract Res Clin Gastroenterol       Date:  2012-08       Impact factor: 3.043

Review 9.  Drug repurposing approach to combating coronavirus: Potential drugs and drug targets.

Authors:  Jimin Xu; Yu Xue; Richard Zhou; Pei-Yong Shi; Hongmin Li; Jia Zhou
Journal:  Med Res Rev       Date:  2020-12-05       Impact factor: 12.944

10.  The Management of Immunosuppression in Kidney Transplant Recipients with COVID-19 Disease: An Update and Systematic Review of the Literature.

Authors:  Roberta Angelico; Francesca Blasi; Tommaso Maria Manzia; Luca Toti; Giuseppe Tisone; Roberto Cacciola
Journal:  Medicina (Kaunas)       Date:  2021-04-30       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.